Effect of the ABCB1 modulators elacridar and tariquidar on the distribution of paclitaxel in nude mice
- 12 October 2007
- journal article
- Published by Springer Science and Business Media LLC in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 134 (5), 597-607
- https://doi.org/10.1007/s00432-007-0323-9
Abstract
Previously, we studied the effect of co-administration of paclitaxel with the second generation ABCB1 (p-gp) modulator valspodar on the intracerebral growth of human U118-MG glioblastoma in nude mice. Valspodar significantly increased the brain levels of paclitaxel by inhibition of p-gp expressed at the blood brain barrier. Thus, the tumour burden was reduced by 90%, which was considered as a proof of concept. However, the paclitaxel dose had to be reduced because of toxic side effects resulting from increased drug levels due to p-gp modulation in peripheral tissues. Therefore, in the present study we examined the co-application of paclitaxel with the third generation ABCB1 modulators elacridar and tariquidar, which were supposed to preferentially modulate p-gp in brain capillaries. The inhibitory activity of the modulators was measured by a flow cytometric and a chemosensitivity assay in vitro. To determine the distribution of paclitaxel in vivo, nude mice received 50 mg/kg of valspodar, elacridar or tariquidar p.o. (control: vehicle) 4 h before i.v. injection of 8 mg/kg of paclitaxel. Brain, liver, kidney and plasma were collected and analyzed by RP-HPLC. Our in vitro experiments demonstrate that the new modulators are about 80 times more effective in comparison to valspodar. Co-administration of paclitaxel with elacridar and tariquidar led to a long lasting fivefold increase in the concentration of the cytostatic in the brain. Although the increase (2.5- to 7-fold) tended to be lower compared to that induced by co-administered valspodar (six- to eightfold), the brain/plasma ratios achieved with the new modulators were 2–15 times higher. Elacridar and tariquidar seem to modulate p-glycoprotein preferentially at the blood–brain barrier. Our results suggest that the systemic toxicity of cytostatics combined with elacridar or tariquidar should be lower than in combination with valspodar.This publication has 40 references indexed in Scilit:
- In vitro activity of novel dual action MDR anthranilamide modulators with inhibitory activity on CYP-450 (Part 2)Bioorganic & Medicinal Chemistry, 2007
- Tariquidar Analogues: Synthesis by CuI‐Catalysed N/O–Aryl Coupling and Inhibitory Activity against the ABCB1 TransporterEuropean Journal of Organic Chemistry, 2007
- Targeting multidrug resistance in cancerNature Reviews Drug Discovery, 2006
- Drug resistance in brain diseases and the role of drug efflux transportersNature Reviews Neuroscience, 2005
- Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoproteinEuropean Journal of Cancer, 2004
- Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and MonkeyThe Journal of pharmacology and experimental therapeutics, 2004
- Assessing Safety and Efficacy of Directed P-Glycoprotein Inhibition to Improve the Pharmacokinetic Properties of Saquinavir Coadministered with RitonavirThe Journal of pharmacology and experimental therapeutics, 2003
- GF120918, a P-Glycoprotein Modulator, Increases the Concentration of Unbound Amprenavir in the Central Nervous System in RatsAntimicrobial Agents and Chemotherapy, 2002
- Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activityZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Vincristine‐resistant Human Cancer KB Cell Line and Increased Expression of Multidrug‐resistance GeneJapanese Journal of Cancer Research, 1988